<DOC>
	<DOCNO>NCT01883076</DOCNO>
	<brief_summary>This Phase I study determine safety feasibility injection autologous umbilical cord blood ( UCB ) cell right ventricle Hypoplastic Left Heart Syndrome ( HLHS ) child undergo schedule Glenn surgical procedure . The investigator research study find autologous stem cell individual 's umbilical cord blood use strengthen muscle right side heart . This help determine safety feasibility use cell-based regenerative therapy additional treatment management HLHS .</brief_summary>
	<brief_title>Safety Study Autologous Umbilical Cord Blood Cells Treatment Hypoplastic Left Heart Syndrome</brief_title>
	<detailed_description>This study Phase I trial determine safety autologous mononuclear cell ( MNC ) derive umbilical cord blood intramyocardial delivery right ventricle plan non-emergent Stage II surgical palliation subject HLHS . This first critical step towards apply autologous MNC therapy add-on regenerative intervention congenital heart disease management . The choice HLHS target disease regenerative therapy congenital heart disease management multi-factorial include following consideration : 1 ) Severity incurable disease , 2 ) palliative nature burden long-term outcome single right ventricular system , 3 ) three stage plan surgical procedure provide time point adjunctively intervene , 4 ) prenatal diagnosis enable plan collection UCB . An emerge goal cardiac regeneration include application cell-based technology congenital heart disease , favorable substrate due lack fibrotic scaring , presence microenvironment expect support ongoing cardiac proliferation growth functional remuscularization . This Phase I safety study determine feasibility collection , processing , delivery autologous cell use adult cardiac regenerative protocol set HLHS surgical management .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
	<criteria>Inclusion Criteria 1 . Individuals autologous cord blood product meet cell release criterion ( list certificate analysis Mayo Clinic Human Cell Therapy Lab ) follow : 1 . No aerobic anaerobic bacterial growth 14 day 2 . Greater 70 % cell viability prefreeze 3 . Total Nucleated Cells ( TNC ) concentration 3042 x 106 cells/mL ( prefreeze ) 4 . Minimum one ( 1 ) vial cell 5 . Mononuclear cell percentage great 50 % 6 . Endotoxin result le 16 Endotoxin Units ( EU ) /mL . 2 . Mother 's serology test result negative HIV , Hepatitis B , Hepatitis C. 3 . Individuals HLHS undergone Stage I surgical palliation undergo plan Stage II palliative Glenn surgery . 4 . Ages 18 month eligible write informed consent obtain parent ( unless one parent reasonably available ) and/or legal guardian . Exclusion Criteria 1 . Child 's UCB meet specify cell release criterion Inclusion Criterion # 1 . 2 . History dimethyl sulfoxide ( DMSO ) reaction either child mother . 3 . Parent ( ) /child unwilling participate . 4 . Child severe chronic disease , extensive extracardiac syndromic feature , history cancer . 5 . Child complete preprocedure workup within 10 day Stage II Glenn surgery list section 6 protocol AND lack preprocedure workup document safety concern site investigator . 6 . Child , reasonably expect , complication Stage II Glenn surgery postoperative recovery . 7 . Child 's cell compromise meeting cell release criterion ( define Inclusion Criterion # 1 ) . 8 . Child follow condition within 15 day prior date Stage II Glenn surgery : 1 . Cardiogenic shock 2 . Changes medical therapy ( e.g . supplemental oxygen , vasodilator ) pulmonary hypertension 3 . Changes arrhythmia medication 4 . A current infection treat oral antibiotic treatment IV antibiotic within past 15 day . 9 . Child follow complication congenital heart disease : 1 . Any condition require urgent , unplanned procedure within 15 day prior Stage II Glenn surgery 2 . Tricuspid repair and/or aortic arch repair time Stage II Glenn surgery 3 . Length hospitalization 60 day Stage I surgical palliation , unless cardiac function normal within 10 day prior Glenn Surgery 4 . Dietary modification due chronic severe chylothorax 5 . Current uncontrolled seizure ( ) neurological injury result persistent deficit 6 . Severe tricuspid regurgitation prior Stage II Glenn surgery 7 . History mechanical circulatory support , unless cardiac function normal within 10 day prior Glenn surgery 8 . Other clinical concern document site investigator could reasonably increase risk complication Stage II Glenn surgery .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypoplastic Left Heart Syndrome</keyword>
	<keyword>HLHS</keyword>
	<keyword>Congenital Heart Disease</keyword>
	<keyword>Umbilical cord blood</keyword>
	<keyword>UCB</keyword>
	<keyword>Cord blood</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Regenerative therapy</keyword>
	<keyword>Stage II Glenn</keyword>
	<keyword>Glenn Surgery</keyword>
</DOC>